Ligand Pharmaceuticals Long Term Debt

Ligand Pharmaceuticals (LGND) currently reports a long-term debt of $700M as of September 2026. That compares with $450M in the prior-year period — up 55.9% year over year. Use the charts on this page to explore Ligand Pharmaceuticals's long-term debt history and peer comparisons.

Ligand Pharmaceuticals's long-term debt increased from $450M to $700M — a 55.9% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ligand Pharmaceuticals reported $700M in long-term debt as of September 2026. That compares with $450M in the prior-year period — up 55.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $700M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ligand Pharmaceuticals, and consider following LGND for alerts when major investors trade the stock.

Ligand Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $700M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LGND with unrelated industries.